Monday, October 26, 2026 · Daily editionET --:--:--

Finished

Impact of the Atlas 2030 Pediatric Exoskeleton on Gait Functionality and Quality of Life in Children With Cerebral Palsy or Related Conditions

NCT07066956 · FIDMAG Germanes Hospitalàries · Updated 15 July 2025

What is being tested
ATLAS 2030 Exoskeleton
For
Cerebral Palsy Infantile
Kind of study
Watches patients without assigning a treatment. No drug phase (a device or procedure study).
Who can join
Ages 2 years to 14 years. About 13 people. The full rules are on the registry page.
Where
Spain
When
Starts or started 1 Jan 2023, ends 31 July 2023. Registered 15 July 2025.
Results
None posted yet.

In the researchers' words

Title of the Study IMPACT OF THE ATLAS 2030 PEDIATRIC EXOSKELETON ON GAIT FUNCTIONALITY AND QUALITY OF LIFE IN CHILDREN WITH CEREBRAL PALSY OR RELATED CONDITIONS Justification Cerebral palsy and gait rehabilitation It is estimated that around 93 million children worldwide have some form of moderate or severe disability. Cerebral palsy (CP) is the most common motor disability in children, with a prevalence of 1.8 per 1,000 live births in Europe. CP causes severe motor dysfunction, sometimes resulting in the inability to stand or walk. This is due to damage in areas of the central nervous system (CNS) that control movement and posture. CP causes a series of signs and symptoms such as spasticity, muscle contractures, incoordination, loss of selective motor control, or weakness, which interfere with motor function and daily living activities in these children. As part of physical therapy, there are different types of pediatric robotic devices that assist with gait. These include: Lokomat, a stationary treadmill-based device; the G-EO System, which is also stationary and has a stair-climbing function; Innowalk, which enables standing; and other similar devices like NX-A3, Robogait, and Walkbot-K. Also notable is Prodrobot, which differs from the above as it performs suspended walking. Walking has been shown to have physiological and functional benefits, including the prevention…
ClinicalTrials.gov, NCT07066956

Sites

  • Ospitalarioak Fundazioa EuskadiArrasate / Mondragón, Basque Country, Spain